NCT05492565View on ClinicalTrials.gov

Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

Enrolling by invitationOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
HIV Infection PrimaryHepatitis, Viral, HumanSexually Transmitted Infections, Excluding HIV and Hepatitis
Interventions
DRUG

Tenofovir Disoproxil Fumarate 300 MG Oral Tablet

Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection

Trial Locations (1)

41013

Virgen del Rocío University Hospital, Seville

All Listed Sponsors
collaborator

Instituto de Biomedicina de Sevilla

UNKNOWN

lead

Hospitales Universitarios Virgen del Rocío

OTHER

NCT05492565 - Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis | Biotech Hunter | Biotech Hunter